MEK1/2 and ERK1/2 mediated lung endothelial injury and altered hemostasis promote diffuse alveolar hemorrhage in murine lupus
Preprint
Abstract
Objective: About 3% of lupus patients develop severe diffuse alveolar hemorrhage (DAH) with pulmonary vasculitis. B6 mice with pristane-induced lupus also develop DAH, but BALB/c mice are resistant. DAH is independent of TLR signaling and other inflammatory pathways. This study examined the role of the mitogen-activated protein kinase pathway (MEK1/2-ERK1/2, JNK, p38). Methods: B6 and BALB/c mice were treated with pristane ± inhibitors of MEK1/2 (trametinib/GSK1120212, “GSK”), ERK1/2 (SCH772984, “SCH”), JNK, or p38. Effects on lung hemorrhage and hemostasis were determined. Results: GSK and SCH abolished DAH, whereas JNK and p38 inhibitors were ineffective. Apoptotic cells were present in lung from pristane-treated mice, but not mice receiving pristane+GSK and endothelial dysfunction was normalized. Expression of the ERK1/2-regulated transcription factor Egr1 increased in pristane-treated B6, but not BALB/c, mice and was normalized by GSK. Pristane also increased expression of the anticoagulant genes Tfpi (tissue factor pathway inhibitor) and Thbd (thrombomodulin) in B6 mice. The ratio of tissue factor ( F3 ) to Tfpi increased in B6 (but not BALB/c) mice and was normalized by GSK. Circulating Thbd protein increased in B6 mice and returned to normal after GSK treatment. Consistent with augmented endothelial anticoagulant activity, pristane treatment increased tail bleeding in B6 mice. Conclusion: Pristane treatment promotes lung endothelial injury and DAH in B6 mice by activating the MEK1/2-ERK1/2 pathway and impairing hemostasis. The hereditary factors determining susceptibility to lung injury and bleeding in pristane-induced lupus are relevant to the pathophysiology of life-threatening DAH in SLE and may help to optimize therapy.Keywords
All Related Versions
- Published version: Arthritis & Rheumatology, 76 (10), 1538.
This publication has 75 references indexed in Scilit:
- Association of serum ferritin with severity and clinical outcome in COVID-19 patients: An observational study in a tertiary healthcare facilityClinical Epidemiology and Global Health, 2023
- Myxomavirus serpin alters macrophage function and prevents diffuse alveolar hemorrhage in pristane-induced lupusClinical Immunology, 2021
- Trametinib (GSK1120212)2018
- Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on ConcizumabDrugs, 2018
- Pathogenesis of Diffuse Alveolar Hemorrhage in Murine LupusArthritis & Rheumatology, 2017
- Clinical Features and Outcomes of Diffuse Alveolar Hemorrhage During Antithrombotic Therapy: A Retrospective Cohort StudyLung, 2016
- Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 Years Institutional ExperienceLung, 2015
- Toll‐like Receptor 7–Stimulated Tumor Necrosis Factor α Causes Bone Marrow Damage in Systemic Lupus ErythematosusArthritis & Rheumatology, 2013
- Infectious Diseases Causing Diffuse Alveolar Hemorrhage in Immunocompetent Patients: A State-of-the-Art ReviewLung, 2012
- Deficiency of the type I interferon receptor protects mice from experimental lupusArthritis & Rheumatism, 2007